Dear Editor, The global impact of TB as a major infectious disease remains highly significant. Despite advances in diagnosis and treatments, leading to a successful cure for most TB patients, many experience enduring tissue or physical damage due to the disease. Post-TB lung disease (PTLD) is defined by ‘evidence of chronic respiratory abnormality, with or without symptoms, attributable at least in part to previous tuberculosis’.1 As of 2020, there are an estimated 155 million TB survivors worldwide, of whom 18–87% may be affected by PTLD.2,3 China has a significant burden of TB, with an estimated 7.1% of global cases in 2022.4 This suggests that there are a significant number of TB survivors at risk of PTLD. However, there is limited epidemiological and clinical data on PTLD in China. We therefore conducted a cross-sectional study at a specialist hospital for TB in Southwest China, to assess the clinical features and chest imaging related to PTLD. We also sought to understand the determinants linked to hospitalisation to address future diagnostic and therapeutic requirements.